Table 3.
Outcome after induction with CPX-351, multivariate analysis.
| Variable | Overall survival | Response rate | ||||
|---|---|---|---|---|---|---|
| P | HR | P | HR | |||
| Prior treatment with HMA | ||||||
| Yes | 0.02 | 2.4 [1.1–5.3] | n.s. | |||
| No | ||||||
| ELN risk stratification | ||||||
| Adverse | <0.0001 | 4.2 [1.9–8.9] | – | |||
| Favorable/intermediate | ||||||
| Karyotype | ||||||
| Complex | – | 0.0001 | 4.3 [1.9–9.2] | |||
| Not complex | ||||||
| NPM1 | ||||||
| wt | n.s. | – | ||||
| mut | ||||||
| TP53 | ||||||
| mut | n.s. | – | ||||
| wt | ||||||
| Age at diagnosis (median) | ||||||
| ≥65 | n.s. | – | ||||
| <65 | ||||||
| Gender | ||||||
| Female | – | n.s. | ||||
| Male | ||||||
ELN European Leukemia Net, HMA hypomethylating agents, HR hazard ratio, mut mutated, n.s. not significant, P p value, wt wild type.